WO2008115973A2 - Aminopyrimidines utiles en tant qu'inhibiteurs de kinase - Google Patents

Aminopyrimidines utiles en tant qu'inhibiteurs de kinase Download PDF

Info

Publication number
WO2008115973A2
WO2008115973A2 PCT/US2008/057465 US2008057465W WO2008115973A2 WO 2008115973 A2 WO2008115973 A2 WO 2008115973A2 US 2008057465 W US2008057465 W US 2008057465W WO 2008115973 A2 WO2008115973 A2 WO 2008115973A2
Authority
WO
WIPO (PCT)
Prior art keywords
compound
optionally substituted
alkyl
aliphatic
compounds
Prior art date
Application number
PCT/US2008/057465
Other languages
English (en)
Other versions
WO2008115973A3 (fr
Inventor
Hayley Binch
Stephen Young
Christopher Davis
Michael Mortimore
Julian Golec
John Studley
Daniel Robinson
Michael O'donnell
Dean Boyall
Joanne Pinder
Simon Everitt
Original Assignee
Vertex Pharmaceuticals Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Incorporated filed Critical Vertex Pharmaceuticals Incorporated
Priority to CN200880014717A priority Critical patent/CN101675041A/zh
Priority to CA002682195A priority patent/CA2682195A1/fr
Priority to JP2009554707A priority patent/JP2010522194A/ja
Priority to MX2009010037A priority patent/MX2009010037A/es
Priority to EP08732458A priority patent/EP2142537A2/fr
Priority to AU2008228963A priority patent/AU2008228963A1/en
Publication of WO2008115973A2 publication Critical patent/WO2008115973A2/fr
Publication of WO2008115973A3 publication Critical patent/WO2008115973A3/fr
Priority to US12/562,181 priority patent/US20100137305A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Definitions

  • the present invention relates to compounds useful as inhibitors of Aurora protein kinases.
  • the invention also relates to pharmaceutically acceptable compositions comprising the compounds of the invention, methods of using the compounds and compositions in the treatment of various disorders, and processes for preparing the compounds.
  • Aurora proteins are a family of three related serine/threonine kinases (termed Aurora-A, -B and -C) that are essential for progression through the mitotic phase of cell cycle. Specifically Aurora-A plays a crucial role in centrosome maturation and segregation, formation of the mitotic spindle and faithful segregation of chromosomes. Aurora-B is a chromosomal passenger protein that plays a central role in regulating the alignment of chromosomes on the meta-phase plate, the spindle assembly checkpoint and for the correct completion of cytokinesis.
  • Aurora kinases are attractive targets due to their association with numerous human cancers and the roles they play in the proliferation of these cancer cells. It would be desirable to have an Aurora kinase inhibitor with favorable drug-like properties, such as stability in human liver microsomes. Accordingly, there is a need for compounds that inhibit Aurora kinases and also exhibit favorable drug-like properties .
  • This invention provides compounds and pharmaceutically acceptable compositions thereof that are useful as inhibitors of Aurora protein kinases. More specifically, this invention provides compounds that are metabolically stable in human liver microsomes and/or potently inhibit cell proliferation. [0007] These compounds are represented by formula I:
  • These compounds and pharmaceutically acceptable compositions thereof are useful for inhibiting kinases in vitro, in vivo, and ex vivo .
  • Such uses include treating or preventing myeloproliferative disorders and proliferative disorders such as melanoma, myeloma, leukemia, lymphoma, neuroblastoma, and cancer.
  • Other uses include the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors .
  • One embodiment of this invention provides a compound of formula I :
  • R 2 is H, Ci-3 alkyl, or cyclopropyl
  • Q is -O-, -S-, or -C(R')2-;
  • R x is H or F
  • R 4 is H, Ci- 5 alkyl, or C 3 - 6 cycloalkyl
  • R 5 is Ci- 5 alkyl or C 3 - 6 cycloalkyl; or R 4 and R 5 , together with the nitrogen atom to which they are bound, form a 3-6 membered monocyclic ring containing 1-2 heteroatoms selected from 0, N, or S; wherein said monocyclic ring is optionally substituted with 0-3 J R ; R 6 is H, Ci- 4 alkyl or C 3 - 6 cycloalkyl; wherein said Ci- 4 alkyl or C3-6 cycloalkyl is optionally substituted with 1-3 fluorine atoms;
  • J R is F or R 7 ;
  • R 1 is phenyl or a 6-membered heteroaryl ring, wherein said heteroaryl has 1-4 ring heteroatoms selected from 0, N, and S; R 1 is optionally substituted with 0-4 occurrences of -NHC(O)R 3 or 0-4 fluorine atoms;
  • R 3 is Ci- ⁇ aliphatic or phenyl, wherein said R 3 is optionally substituted with 0-6 J 3 ; each J 3 is independently halo, Ci- ⁇ alkyl, -O- (Ci- ⁇ alkyl) ,
  • Ci- ⁇ alkyl group is optionally substituted with 0-3 flourine atoms; or two J 3 groups, together with the carbon atom to which they are bound, form a 3-5 membered monocyclic group containing 0-1 heteroatom selected from O, N, and S; each R 7 is independently Ci-6 aliphatic; a 5-6 membered heteroaryl containing 1-4 heteroatoms selected from O, N, or S; each R 7 is optionally substituted with 0-3 J 7 ; and
  • J 7 is independently NH 2 , NH (Ci- 4 aliphatic) , N (Ci- 4 aliphatic) 2 , halogen, Ci_ 4 aliphatic, OH, O (Ci_ 4 aliphatic) , NO 2 , CN, CO 2 H, CO 2 (Ci- 4 aliphatic) , 0 (haloCi- 4 aliphatic) , or haloCi- 4 aliphatic .
  • R 2 is cyclopropyl, R 2 is H, Q is S, R 1 is phenyl,
  • R x is H, Ht is ; R 2 is methyl, R 2' is H, Q is S, R 1 is phenyl, and R 3 is ethyl; then R ⁇ is not
  • One embodiment of this invention provides a compound of formula I or a pharmaceutically acceptable salt thereof, wherein the variables are as defined herein:
  • n is 1.
  • Q is S.
  • R x is H.
  • R 2 is H or optionally substituted
  • R 2 is C 1 -3 alkyl or cyclopropyl . In some embodiments, R 2 is C 1 -3 alkyl.
  • R 2' is H. In other embodiments,
  • R 2' is H and R 2 is C 1 -3 alkyl or cyclopropyl.
  • R 1 is phenyl. In some of these embodiments, R 1 is substituted at the para position. In some embodiments, R 1 is optionally substituted with 1 occurrence of
  • R 1 is
  • R 3 is Ci- ⁇ aliphatic wherein said R 3 is optionally substituted with 0-6 J 3 . In some embodiments, R 3
  • R is phenyl.
  • R 3 is substituted in the ortho position with J 3 .
  • J 3 is halogen, CF 3 , Ci- 3 alkyl, -S- (Ci_ 3 alkyl) , or OCF 3 .
  • Ht is
  • Ht is [0023] In some embodiments, n is 1 In other embodiments, n is 2.
  • J 2 is independently Ci- ⁇ alkyl, F, NR 4 R 5 , CN, OR 6 , or R 7 .
  • J 1 is F. In other embodiments, J 1 is NR 4 R 5 .
  • R 4 and R 5 together with the nitrogen atom to which they are bound, form a 5-6 membered monocyclic ring containing 1-2 heteroatoms selected from O, N, or S; wherein said monocyclic ring is optionally substituted with 0-3 J R .
  • said monocyclic ring is a ring selected from piperidine, piperazine, morpholine, or pyrrolidine.
  • said piperidine, piperazine, morpholine, or pyrrolidine ring is optionally substituted with F or R 7 .
  • R 7 is Ci- 6 aliphatic .
  • n is 2. In some embodiments,
  • R ⁇ and n is 2.
  • two J 2 groups together with the atom(s) to which they are bound, form a 4-7 membered heterocyclyl ring containing 1-2 heteroatoms selected from N or O; wherein said ring is optionally substituted with 0-3 J R .
  • the two J 2 groups are attached to the same atom to form a spirocyclic compound.
  • said heterocyclyl ring contains 1 heteroatom.
  • said heteroatom is nitrogen.
  • said heterocyclyl ring is selected from piperidine or pyrrolidine.
  • said heterocyclyl ring is optionally substituted with 1 J R .
  • J R is R 7 and the R 7 is Ci-6 aliphatic.
  • R 7 is Ci- ⁇ alkyl.
  • R 7 is methyl.
  • R ⁇ is HN- ⁇ v ⁇ / _ j n other
  • R is [0033] Another embodiment provides compounds wherein R ⁇ is . In some embodiments, n is 1. In some embodiments,
  • J 1 is F and R 1 is substituted with 1 occurrence of -NHC(O)R 3 .
  • R 3 is Ci- 6 aliphatic, wherein said R 3 is substituted with 0-6 J 3 ;
  • each J is halo.
  • R is CH 2 CF 3 .
  • RR 33 is CH 2 CH 2 CF 3 .
  • R 3 is ethyl or cyclopropyl .
  • R ⁇ is In other
  • R ⁇ is
  • R ⁇ is , n is 1, J 1 is NR 4 R 5 , R 1 is substituted with 1 occurrence of -NHC(O)R 3 , and R 3 is Ci- 6 aliphatic, wherein said R 3 is substituted with 0-6 J 3 ;
  • each J 3 is halo. In some embodiments, R ⁇ .
  • Formula II include those shown in Table 1 below.
  • compounds of the invention may optionally be substituted with one or more substituents, such as are illustrated generally above, or as exemplified by particular classes, subclasses, and species of the invention. It will be appreciated that the phrase “optionally substituted” is used interchangeably with the phrase “substituted or unsubstituted. " In general, the term “substituted”, whether preceded by the term “optionally” or not, refers to the replacement of hydrogen radicals in a given structure with the radical of a specified substituent .
  • an optionally substituted group may have a substituent at each substitutable position of the group, and when more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at every position.
  • Combinations of substituents envisioned by this invention are preferably those that result in the formation of stable or chemically feasible compounds.
  • stable refers to compounds that are not substantially altered when subjected to conditions to allow for their production, detection, and preferably their recovery, purification, and use for one or more of the purposes disclosed herein.
  • a stable compound or chemically feasible compound is one that is not substantially altered when kept at a temperature of 40 0 C or less, in the absence of moisture or other chemically reactive conditions, for at least a week.
  • aliphatic or "aliphatic group”, and the like, as used herein, means an unbranched or branched, straight-chain or cyclic, substituted or unsubstituted hydrocarbon that is completely saturated or that contains one or more units of unsaturation that has a single point of attachment to the rest of the molecule.
  • Suitable aliphatic groups include, but are not limited to, linear or branched, substituted or unsubstituted alkyl, alkenyl, or alkynyl groups.
  • Specific examples include, but are not limited to, methyl, ethyl, isopropyl, n-propyl, sec-butyl, vinyl, n- butenyl, ethynyl, tert-butyl, cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, or cyclopentylethyl .
  • cycloaliphatic refers to a monocyclic C3-C8 hydrocarbon or bicyclic C8-C12 hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic, that has a single point of attachment to the rest of the molecule wherein any individual ring in said bicyclic ring system has 3-7 members.
  • Suitable cycloaliphatic groups include, but are not limited to, cycloalkyl and cycloalkenyl groups. Specific examples include, but are not limited to, cyclohexyl, cyclopropenyl, and cyclobutyl.
  • alkyl as used herein, means an unbranched or branched, straight-chain or cyclic hydrocarbon that is completely saturated and has a single point of attachment to the rest of the molecule. Unless otherwise indicated, alkyl groups contain 1-12 carbon atoms. Specific examples of alkyl groups include, but are not limited to, methyl, ethyl, isopropyl, n-propyl, cyclopropyl, sec-butyl, and cyclobutyl. [0047] In the compounds of this invention, rings include linearly-fused, bridged, or spirocyclic rings. Examples of bridged cycloaliphatic groups include, but are not limited to, bicyclo [3.3.2] decane, bicyclo [3.1.1] heptane, and bicyclo [3.2.2] nonane .
  • heterocycle means non- aromatic, monocyclic or bicyclic ring in which one or more ring members are an independently selected heteroatom.
  • the "heterocycle”, “heterocyclyl”, or “heterocyclic” group has three to ten ring members in which one or more ring members is a heteroatom independently selected from oxygen, sulfur, nitrogen, or phosphorus, and each ring in the system contains 3 to 7 ring members.
  • bridged heterocycles include, but are not limited to, 7-aza-bicyclo [2.2.1] heptane and 3-aza- bicyclo [3.2.2] nonane .
  • Suitable heterocycles include, but are not limited to, 3-lH-benzimidazol-2-one, 3- (1-alkyl) -benzimidazol-2-one, 2- tetrahydrofuranyl, 3-tetrahydrofuranyl, 2- tetrahydrothiophenyl, 3-tetrahydrothiophenyl, 2-morpholino, 3- morpholino, 4-morpholino, 2-thiomorpholino, 3-thiomorpholino, 4-thiomorpholino, 1-pyrrolidinyl, 2-pyrrolidinyl, 3- pyrrolidinyl, 1-tetrahydropiperazinyl, 2- tetrahydropiperazinyl, 3-tetrahydropiperazinyl, 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 1-pyrazolinyl, 3-pyrazolinyl, 4- pyrazolinyl, 5-pyrazolinyl, 1-piperidinyl, 2-piperidin
  • heteroatom means one or more of oxygen, sulfur, nitrogen, phosphorus, or silicon (including, any oxidized form of nitrogen, sulfur, phosphorus, or silicon; the quaternized form of any basic nitrogen or; a substitutable nitrogen of a heterocyclic ring, for example N (as in 3,4- dihydro-2i ⁇ -pyrrolyl) , NH (as in pyrrolidinyl) or NR + (as in N- substituted pyrrolidinyl) ) .
  • aryl refers to monocyclic, or bicyclic ring having a total of five to twelve ring members, wherein at least one ring in the system is aromatic and wherein each ring in the system contains 3 to 7 ring members.
  • aryl may be used interchangeably with the term “aryl ring”.
  • aryl also refers to heteroaryl ring systems as defined hereinbelow .
  • heteroaryl refers to monocyclic or bicyclic ring having a total of five to twelve ring members, wherein at least one ring in the system is aromatic, at least one ring in the system contains one or more heteroatoms, and wherein each ring in the system contains 3 to 7 ring members.
  • heteroaryl may be used interchangeably with the term “heteroaryl ring” or the term “heteroaromatic” .
  • Suitable heteroaryl rings include, but are not limited to, 2-furanyl, 3-furanyl, N-imidazolyl, 2-imidazolyl, 4-imidazolyl, 5- imidazolyl, benzimidazolyl, 3-isoxazolyl, 4-isoxazolyl, 5- isoxazolyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, N-pyrrolyl, 2- pyrrolyl, 3-pyrrolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2- pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, pyridazinyl (e.g., 3-pyridazinyl) , 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, tetrazolyl (e.g., 5-tetrazolyl) , triazolyl (e.g., 2-triazolyl and 5-triazo
  • the term "unsaturated”, as used herein, means that a moiety has one or more units of unsaturation .
  • the term “halogen” means F, Cl, Br, or I.
  • the term "protecting group”, as used herein, refers to an agent used to temporarily block one or more desired reactive sites in a multifunctional compound.
  • a protecting group has one or more, or preferably all, of the following characteristics: a) reacts selectively in good yield to give a protected substrate that is stable to the reactions occurring at one or more of the other reactive sites; and b) is selectively removable in good yield by reagents that do not attack the regenerated functional group. Exemplary protecting groups are detailed in Greene, T.
  • structures depicted herein are also meant to include all isomeric (e.g., enantiomeric, diastereomeric, and geometric (or conformational) ) forms of the structure; for example, the R and S configurations for each asymmetric center, (Z) and (E) double bond isomers, and (Z) and (E) conformational isomers. Therefore, single stereochemical isomers as well as enantiomeric, diastereomeric, and geometric (or conformational) mixtures of the present compounds are within the scope of the invention. [0058] Unless otherwise indicated, all tautomeric forms of the compounds of the invention are within the scope of the invention. As would be understood by a skilled practitioner, a pyrazole group can be represented in a variety of ways. For
  • a structure drawn a also represents other
  • structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms.
  • compounds having the present structures except for the replacement of hydrogen by deuterium or tritium, or the replacement of a carbon by a 13 C- or 14 C- enriched carbon are within the scope of this invention.
  • Such compounds are useful, for example, as analytical tools or probes in biological assays.
  • the compounds of this invention may be prepared in light of the specification using steps generally known to those of ordinary skill in the art. Those compounds may be analyzed by known methods, including but not limited to LCMS (liquid chromatography mass spectrometry) and NMR (nuclear magnetic resonance) . It should be understood that the specific conditions shown below are only examples, and are not meant to limit the scope of the conditions that can be used for making compounds of this invention. Instead, this invention also includes conditions that would be apparent to those skilled in that art in light of this specification for making the compounds of this invention. Unless otherwise indicated, all variables in the following scheme are as defined herein. Scheme I
  • the amino-heteoraryl can be added first, followed by addition of the pyrrolidine or piperdine, oxidation, and finally addition of -Q-R 1 .
  • oxidation can occur first, followed by addition of -Q-R 1 , addition of the amino-heteroaryl, and finally addition of the pyrrolidine or piperdine.
  • R ⁇ is a ring substituted with 1 J 1 or 2-3 J 2 (the 1 J 1 or 2-3 J 2 being depicted above as 1-3 J groups) .
  • the compounds of this invention may be prepared according to the methods shown in WO 2004/000833. [0065] Accordingly, this invention relates to processes for making the compounds of this invention.
  • Alternate in vitro assays quantitate the ability of the inhibitor to bind to the protein kinase and may be measured either by radiolabelling the inhibitor prior to binding, isolating the inhibitor/kinase complex and determining the amount of radiolabel bound, or by running a competition experiment where new inhibitors are incubated with the kinase bound to known radioligands.
  • Aurora protein kinase inhibitors or pharmaceutical salts thereof may be formulated into pharmaceutical compositions for administration to animals or humans. These pharmaceutical compositions, which comprise an amount of the Aurora protein inhibitor effective to treat or prevent an Aurora-mediated condition and a pharmaceutically acceptable carrier, are another embodiment of the present invention.
  • Aurora-mediated condition or “Aurora- mediated disease” as used herein means any disease or other deleterious condition in which Aurora (Aurora A, Aurora B, and Aurora C) is known to play a role.
  • Such conditions include, without limitation, cancer, proliferative disorders, and myeloproliferative disorders.
  • myeloproliferative disorders include, but are not limited, to, polycythemia vera, thrombocythemia, myeloid metaplasia with myelofibrosis, chronic myelogenous leukaemia (CML) , chronic myelomonocytic leukemia, hypereosinophilic syndrome, juvenile myelomonocytic leukemia, and systemic mast cell disease.
  • CML chronic myelogenous leukaemia
  • chronic myelomonocytic leukemia chronic myelomonocytic leukemia
  • hypereosinophilic syndrome juvenile myelomonocytic leukemia
  • systemic mast cell disease systemic mast cell disease
  • cancer also includes, but is not limited to, the following cancers: epidermoid Oral : buccal cavity, lip, tongue, mouth, pharynx; Cardiac : sarcoma (angiosarcoma, fibrosarcoma, rhabdomyosarcoma, liposarcoma) , myxoma, rhabdomyoma, fibroma, lipoma and teratoma; Lung: bronchogenic carcinoma (squamous cell or epidermoid, undifferentiated small cell, undifferentiated large cell, adenocarcinoma) , alveolar (bronchiolar) carcinoma, bronchial adenoma, sarcoma, lymphoma, chondromatous hamartoma, mesothelioma; Gastrointestinal: esophagus (squamous cell carcinoma, larynx, adenocarcinoma, leio
  • the term "cancerous cell” as provided herein includes a cell afflicted by any one of the above-identified conditions.
  • the cancer is selected from colorectal, thyroid, or breast cancer.
  • the compounds of this invention are useful for treating cancer, such as colorectal, thyroid, breast, and lung cancer; and myeloproliferative disorders, such as polycythemia vera, thrombocythemia, myeloid metaplasia with myelofibrosis, chronic myelogenous leukemia, chronic myelomonocytic leukemia, hypereosinophilic syndrome, juvenile myelomonocytic leukemia, and systemic mast cell disease.
  • the compounds of this invention are useful for treating hematopoietic disorders, in particular, acute-myelogenous leukemia (AML) , chronic- myelogenous leukemia (CML) , acute-promyelocytic leukemia (APL) , and acute lymphocytic leukemia (ALL) .
  • AML acute-myelogenous leukemia
  • CML chronic- myelogenous leukemia
  • APL acute-promyelocytic leukemia
  • ALL acute lymphocytic leukemia
  • pharmaceutically acceptable derivatives or prodrugs of the compounds of this invention may also be employed in compositions to treat or prevent the above-identified disorders .
  • a "pharmaceutically acceptable derivative or prodrug” means any pharmaceutically acceptable ester, salt of an ester or other derivative of a compound of this invention which, upon administration to a recipient, is capable of providing, either directly or indirectly, a compound of this invention or an inhibitorily active metabolite or residue thereof.
  • Such derivatives or prodrugs include those that increase the bioavailability of the compounds of this invention when such compounds are administered to a patient (e.g., by allowing an orally administered compound to be more readily absorbed into the blood) or which enhance delivery of the parent compound to a biological compartment (e.g., the brain or lymphatic system) relative to the parent species .
  • Examples of pharmaceutically acceptable prodrugs of the compounds of this invention include, without limitation, esters, amino acid esters, phosphate esters, metal salts and sulfonate esters.
  • the compounds of this invention can exist in free form for treatment, or where appropriate, as a pharmaceutically acceptable salt.
  • the term "pharmaceutically acceptable salt” refers to salts of a compound which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio.
  • Pharmaceutically acceptable salts of the compounds of this invention include those derived from suitable inorganic and organic acids and bases. These salts can be prepared in situ during the final isolation and purification of the compounds. Acid addition salts can be prepared by 1) reacting the purified compound in its free-based form with a suitable organic or inorganic acid and 2) isolating the salt thus formed.
  • Suitable acid salts include acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptanoate, glycerophosphate, glycolate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2- hydroxyethanesulfonate, lactate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oxalate, palmoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate,
  • Base addition salts can be prepared by 1) reacting the purified compound in its acid form with a suitable organic or inorganic base and 2) isolating the salt thus formed.
  • Salts derived from appropriate bases include alkali metal (e.g., sodium and potassium), alkaline earth metal (e.g., magnesium), ammonium and N + (Ci- 4 alkyl) 4 salts. This invention also envisions the quaternization of any basic nitrogen-containing groups of the compounds disclosed herein. Water or oil-soluble or dispersible products may be obtained by such quaternization .
  • Base addition salts also include alkali or alkaline earth metal salts.
  • Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like.
  • Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, loweralkyl sulfonate and aryl sulfonate.
  • Other acids and bases while not in themselves pharmaceutically acceptable, may be employed in the preparation of salts useful as intermediates in obtaining the compounds of the invention and their pharmaceutically acceptable acid or base addition salts.
  • Pharmaceutically acceptable carriers that may be used in these pharmaceutical compositions include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene- polyoxypropylene-block polymers, polyethylene glycol and wool fat.
  • ion exchangers alumina, aluminum stearate, lecithin
  • serum proteins such as human serum albumin
  • buffer substances such as phosphates, glycine, sorbic
  • compositions of the present invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir.
  • parenteral as used herein includes subcutaneous, intravenous, intramuscular, intraarticular, intra-synovial, intrasternal, intrathecal, intraperitoneal, intrahepatic, intralesional and intracranial injection or infusion techniques.
  • Sterile injectable forms of the compositions of this invention may be aqueous or oleaginous suspension. These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents.
  • the sterile injectable preparation may also be a sterile injectable solution or suspension in a nontoxic parenterally-acceptable diluent or solvent, for example as a solution in 1, 3-butanediol .
  • the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • a bland fixed oil may be employed including synthetic mono- or di-glycerides .
  • Fatty acids such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions.
  • These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, such as carboxymethyl cellulose or similar dispersing agents which are commonly used in the formulation of pharmaceutically acceptable dosage forms including emulsions and suspensions.
  • Other commonly used surfactants such as Tweens, Spans and other emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms may also be used for the purposes of formulation .
  • compositions of this invention may be administered in the form of suppositories for rectal administration.
  • suppositories for rectal administration.
  • a suitable non-irritating excipient which is solid at room temperature but liquid at rectal temperature and therefore will melt in the rectum to release the drug.
  • suitable non-irritating excipient may include cocoa butter, beeswax and polyethylene glycols .
  • Suitable carriers may include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.
  • the pharmaceutical compositions may be formulated as micronized suspensions in isotonic, pH adjusted sterile saline, or as solutions in isotonic, pH adjusted sterile saline, either with or without a preservative such as benzylalkonium chloride.
  • the pharmaceutical compositions may be formulated in an ointment such as petrolatum.
  • compositions of this invention may also be administered by nasal aerosol or inhalation.
  • Such compositions may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other conventional solubilizing or dispersing agents.
  • the amount of kinase inhibitor that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated, the particular mode of administration, and the indication.
  • the compositions should be formulated so that a dosage of between 0.01 - 100 mg/kg body weight/day of the inhibitor can be administered to a patient receiving these compositions.
  • the compositions should be formulated so that a dosage of between 0.1 - 100 mg/kg body weight/day of the inhibitor can be administered to a patient receiving these compositions .
  • a specific dosage and treatment regimen for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, and the judgment of the treating physician and the severity of the particular disease being treated.
  • the amount of inhibitor will also depend upon the particular compound in the composition.
  • the invention provides methods for treating or preventing cancer, a proliferative disorder, or a myeloproliferative disorder comprising the step of administering to a patient one of the herein-described compounds or pharmaceutical compositions.
  • said method is used to treat or prevent a hematopoietic disorder, such as acute-myelogenous leukemia (AML) , acute-promyelocytic leukemia (APL) , chronic- myelogenous leukemia (CML) , or acute lymphocytic leukemia (ALL) .
  • AML acute-myelogenous leukemia
  • APL acute-promyelocytic leukemia
  • CML chronic- myelogenous leukemia
  • ALL acute lymphocytic leukemia
  • said method is used to treat or prevent myeloproliferative disorders, such as polycythemia vera, thrombocythemia, myeloid metaplasia with myelofibrosis, chronic myelogenous leukaemia (CML) , chronic myelomonocytic leukemia, hypereosinophilic syndrome, juvenile myelomonocytic leukemia, and systemic mast cell disease.
  • myeloproliferative disorders such as polycythemia vera, thrombocythemia, myeloid metaplasia with myelofibrosis, chronic myelogenous leukaemia (CML) , chronic myelomonocytic leukemia, hypereosinophilic syndrome, juvenile myelomonocytic leukemia, and systemic mast cell disease.
  • Another aspect of the invention relates to inhibiting kinase activity in a patient, which method comprises administering to the patient a compound of formula I or a composition comprising said compound.
  • said kinase is an Aurora kinase (Aurora A, Aurora B, Aurora C), AbI, Arg, FGFRl, MELK, MLKl, MuSK, Ret, or TrkA.
  • additional drugs may be administered together with the compounds of this invention. In some cases, these additional drugs are normally administered to treat or prevent the same condition.
  • chemotherapeutic agents or other anti-proliferative agents may be combined with the compounds of this invention to treat proliferative diseases .
  • said therapeutic agent is selected from camptothecin, doxorubicin, idarubicin, Cisplatin, taxol, taxotere, vincristine, tarceva, the MEK inhibitor, U0126, a KSP inhibitor, vorinostat, Gleevec, dasatinib, and nilotinib.
  • said therapeutic agent is dasatnib.
  • said therapeutic agent is selected from Her-2 inhibitors (such as Herceptin) ; HDAC inhibitors (such as vorinostat) , VEGFR inhibitors (such as Avastin) , c-KIT and FLT-3 inhibitors (such as sunitinib) , BRAF inhibitors (such as Bayer's BAY 43-9006) MEK inhibitors (such as Pfizer' s PD0325901); and spindle poisons (such as Epothilones and paclitaxel protein-bound particles (such as Abraxane® ) .
  • Her-2 inhibitors such as Herceptin
  • HDAC inhibitors such as vorinostat
  • VEGFR inhibitors such as Avastin
  • c-KIT and FLT-3 inhibitors such as sunitinib
  • BRAF inhibitors such as Bayer's BAY 43-9006
  • MEK inhibitors such as Pfizer' s PD0325901
  • spindle poisons such as Epothilones and
  • a compound of the instant invention may also be useful for treating cancer in combination with the following therapeutic agents: abarelix (Plenaxis depot®); aldesleukin (Prokine®) ; Aldesleukin (Proleukin®) ; Alemtuzumabb (Campath®) ; alitretinoin (Panretin®) ; allopurinol (Zyloprim®) ; altretamine (Hexalen®) ; amifostine (Ethyol®) ; anastrozole (Arimidex®) ; arsenic trioxide (Trisenox®) ; asparaginase (Elspar®) ; azacitidine (Vidaza®) ; bevacuzimab (Avastin®) ; bexarotene capsules (Targretin®) ; bexarotene gel (Targretin®) ; bleomycin (Blenoxane®) ;
  • Another embodiment provides a simultaneous, separate or sequential use of a combined preparation.
  • Those additional agents may be administered separately, as part of a multiple dosage regimen, from the kinase inhibitor-containing compound or composition.
  • those agents may be part of a single dosage form, mixed together with the kinase inhibitor in a single composition .
  • Rt(min) refers to the HPLC retention time, in minutes, associated with the compound. Unless otherwise indicated, the HPLC method utilized to obtain the reported retention time is as follows: Column: ACE C8 column, 4.6 x 150 mm
  • a microwave vial was charged with N- (4- (4-chloro-6- (3-methyl-lH-pyrazol-5-ylamino) pyrimidin-2-ylthio) phenyl) - 3, 3, 3-trifluoropropanamide (2.5 g, 5.92 mmol), cis- Octahydropyrrolo [3, 4-b] pyridine (2.23 g, 17.8 mmol), diisopropylethylamine (10.3 ml, 59.2 mmol) and dioxane (30 ml) .
  • the vial was heated at 130 0 C for 90 minutes in the CEM microwave.
  • reaction mixture was diluted with ethyl acetate, washed with a saturated sodium bicarbonate solution and brine. The organic layer was dried over magnesium sulfate and concentrated in vacuo. The residue was purified by reverse phase preparative HPLC [Waters Sunfire C18, lO ⁇ M, 100 A column, gradient 10% - 95% B (solvent A: 0.05% TFA in water; solvent B: CH3CN) over 16 minutes at 25 mL/min] to give the desired product as a trifluoroacetic acid salt (620 mg, 16% yield).
  • R y H moieties used in the preparation of compounds of formula I can be prepared via a sequence similar to the one described example 3 (methods I and J) : 3-tert- butylpyrrolidin-3-ol 2, 2, 2-trifluoroacetate; 4-ethylpiperidin- 4-ol 2, 2, 2-trifluoroacetate; 4-isopropylpiperidin-4-ol 2,2,2- trifluoroacetate; 4-tert-butylpiperidin-4-ol 2,2,2- trifluoroacetate .
  • Example 4 3-tert- butylpyrrolidin-3-ol 2, 2, 2-trifluoroacetate; 4-ethylpiperidin- 4-ol 2, 2, 2-trifluoroacetate; 4-isopropylpiperidin-4-ol 2,2,2- trifluoroacetate; 4-tert-butylpiperidin-4-ol 2,2,2- trifluoroacetate .
  • Example 4 Example 4 :
  • R y H moieties used in the preparation of compounds of formula I can be prepared via a sequence similar to the one described example 4 (methods K and J) : 2,2- dimethyl-1, 3 ' -bipyrrolidine 2, 2, 2-trifluoroacetate; 4- (2, 2- dimethylpyrrolidin-1-yl) piperidine 2,2, 2-trifluoroacetate;
  • R y H moieties used in the preparation of compounds of formula I can be prepared via a sequence similar to the one described in example 6 (methods M, N and O) : (S)- N, N-dimethylpiperidin-3-amine hydrochloride; (R) -1,3'- bipyrrolidine hydrochloride, (S) -N-ethyl-N-methylpyrrolidin-3- amine hydrochloride, (S) -1, 3 ' -bipyrrolidine hydrochloride.
  • R y H moieties comprised in compounds of formula I of this invention can be prepared via method O: octahydro- lH-pyrrolo [ 3, 4-b] pyridine dihydrochloride .
  • Example 7 3-methylpyrrolidin-3-ol
  • (S) -3-methoxypyrrolidine hydrochloride was prepared from (S)- tert-butyl 3-methoxypyrrolidine-l-carboxylate by using method O.
  • R y H moieties used in the preparation of compounds of formula I can be prepared via a sequence similar to the one described in example 9 (methods S and J) : 2- isopropyl-2 , 7-diazaspiro [4.4] nonane bis (2,2,2- trifluoroacetate) , 2-isopropyloctahydropyrrolo [3, 4-c] pyrrole bis (2, 2 , 2-trifluoroacetate) .
  • Example 10 2- isopropyl-2 , 7-diazaspiro [4.4] nonane bis (2,2,2- trifluoroacetate) , 2-isopropyloctahydropyrrolo [3, 4-c] pyrrole bis (2, 2 , 2-trifluoroacetate) .
  • decane- 8-carboxylate 1.3 g, 4.84 mmol was taken up in tetrahydrofuran (25 ml) and cooled down to 0 0 C. Borane 1 M in tetrahydrofuran (15 ml, 15 mmol) was added dropwise. The reaction mixture was then heated to reflux for 18 hours. The reaction was cooled down to 0 0 C, quenched with methanol (15 ml), and concentrated in vacuo to give the desired compound (1.23 g, quantitative yield).
  • 2-methyl-2, 8-diazaspiro [4.5] decane hydrochloride was prepared from tert-butyl 2-methyl-2, 8-diazaspiro [ 4.5] decane-8- carboxylate by using method O.
  • Ethyl chloroformate (1.64 ml, 17 mmol) was added dropwise to a solution of 1- (tert-butoxycarbonyl) -4- methylpiperidine-4-carboxylic acid (2.7 g, 11 mmol) and triethylamine (2.1 ml, (15.5 mmol) in tetrahydrofuran (40 ml) cooled to -15°C. The solution was stirred at -15°C for 20 minutes. Sodium azide (1.44 g, 22 mmol) was added and the reaction mixture was stirred at -15°C for a further 1 hour before allowing it to warm up to room temperature. The reaction mixture was partitioned between water and toluene.
  • Benzyl chloroformate (4.99 ml, 34.98 mmol) was added dropwise to a solution of ethyl isonipecotate (5.0 g, 31.8 mmol) and triethylamine (5.76 ml, 41.34 mmol) in chloroforme (70 ml) at 0 0 C. After addition, the reaction mixture was stirred at 0 0 C for 1 hour, then allowed to warm up to room temperateure and stirred for 18 hours. The reaction mixture was washed with 1 M HCl twice and brine. The solution was dried over magnesium sulfate and concentrated in vacuo.
  • l-benzyl-N-tert-butylpiperidin-4-amine was prepared from N-Benzyl-4-piperidone and tert-Butylamine by using method K.
  • 1 H NMR (CDCl 3 , 400 MHz) ⁇ l.12 (9H, s) , 1.35-1.55 (2H, m) , 1.60-1.55 (3H, m) , 2.04 (2H, dt) , 2.54 (IH, m) , 2.85 (2H, td) , 3.51 (2H, d) , 7.25-7.35 (5H, m) .
  • N-tert-butyl-N-methylpiperidin-4-amine was prepared from l-benzyl-N-tert-butyl-N-methylpiperidin-4-amine by using method Q.
  • R 1 QH moieties used in the preparation of compounds of formula I of this invention can be prepared via a sequence similar to the one described in example 14 (method FF) : 3, 3, 3-trifluoro-N- (4- mercaptophenyl) propanamide .
  • R 1 QH moieties used in the preparation of compounds of formula I wherein Q is a sulfur atom can be prepared via a sequence similar to the one described in example 15 (methods GG and HH): 4 , 4 , 4-trifluoro-N- (4- mercaptophenyl) butanamide, N- (4-mercaptophenyl) -1- (trifluoromethyl) cyclopropanecarboxamide, 2 , 2-difluoro-N- (4- mercaptophenyl) cyclopropanecarboxamide, 2-cyclopropyl-N- (4- mercaptophenyl) acetamide, 2-cyclopentyl-N- (4- mercaptophenyl) acetamide, 2-chloro-N- (4- mercaptophenyl) benzamide, N- (4-mercaptophenyl) -2- (trifluoromethyl) benzamide .
  • Example 16 Example 16:
  • Triethylamine (8 ml, 57.40 mmol) was added to a solution of 2-fluoro-4-iodoaniline (11 g, 46.41 mmol) in tetrahydrofuran (60 ml) cooled down to 0 0 C.
  • Tris- (2-carboxyethyl) phosphine hydrochloride (TCEP. HCl, 2.3 g, 8.04 mmol) was added to a solution of N, N'- (4,4' -disulfanediylbis (2-fluoro-4 , 1-phenylene) ) dicyclopropanecarboxamide (3.31 g, 7.87 mmol) and triethylamine (1.1 ml, 7.91 mmol) in a mixture of water (2 ml) and dimethylformamide (10 ml) . The reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was diluted with water (200 ml) .
  • R 1 QH moieties used in the preparation of compounds of formula I wherein Q is a sulfur atom can be prepared via a sequence similar to the one described in example 16 (methods II, JJ and KK): N- (3-fluoro-4- mercaptophenyl) cyclopropanecarboxamide .
  • Example 17 Aurora-2 (Aurora A) Inhibition Assay
  • Compounds were screened for their ability to inhibit Aurora-2 using a standard coupled enzyme assay (Fox et al . , Protein Sci . , (1998) 7, 2249) . Assays were carried out in a mixture of 10OmM Hepes (pH7.5), 1OmM MgCl 2 , ImM DTT, 25mM NaCl, 2.5mM phosphoenolpyruvate, 300 ⁇ M NADH, 30 ⁇ g/ml pyruvate kinase and 10 ⁇ g/ml lactate dehydrogenase.
  • IC50 and Ki data were calculated from non-linear regression analysis using the Prism software package (GraphPad Prism version 3.0cx for Macintosh, GraphPad Software, San Diego California, USA) .
  • Prism software package GraphPad Prism version 3.0cx for Macintosh, GraphPad Software, San Diego California, USA.
  • Compounds 1-2 to 1-7, 1-9 to 1-12, 1-14 to 1-27, 1-29 to 1-85 were found to have Aurora A kinase activity at ⁇ 10 nM Ki.
  • Example 18 Aurora-1 (Aurora B) Inhibition Assay (radiometric) [00183] An assay buffer solution was prepared which consisted of 25 mM HEPES (pH 7.5), 10 mM MgCl 2 , 0.1% BSA and 10% glycerol. A 22 nM Aurora-B solution, also containing 1.7 mM DTT and 1.5 mM Kemptide (LRRASLG), was prepared in assay buffer. To 22 ⁇ L of the Aurora-B solution, in a 96-well plate, was added 2 ⁇ l of a compound stock solution in DMSO and the mixture allowed to equilibrate for 10 minutes at 25°C.
  • the enzyme reaction was initiated by the addition of 16 ⁇ l stock [ ⁇ - 33 P] -ATP solution ( ⁇ 20 nCi/ ⁇ L) prepared in assay buffer, to a final assay concentration of 800 ⁇ M. The reaction was stopped after 3 hours by the addition of 16 ⁇ L 500 mM phosphoric acid and the levels of 33 P incorporation into the peptide substrate were determined by the following method. [00184] A phosphocellulose 96-well plate (Millipore, Cat no. MAPHNOB50) was pre-treated with 100 ⁇ L of a 100 mM phosphoric acid prior to the addition of the enzyme reaction mixture (40 ⁇ L) .
  • Ki values were calculated from initial rate data by non-linear regression using the Prism software package (Prism 3.0, Graphpad Software, San Diego, CA).
  • Prism 3.0, Graphpad Software, San Diego, CA Prism 3.0, Graphpad Software, San Diego, CA.
  • the liquid handler was programmed (WinPREP software) to sample the microsomal incubation mixture after 0, 2, 10, 30 and 60 minutes of incubation and transfer an aliquot (100 ⁇ L) to a stop block (96-well block) containing 100 ⁇ L of chilled methanol.
  • the % organic in the stop mixture was optimized for analysis by addition of appropriate volumes of aqueous/organic (typically 100 ⁇ L of 50:50 methanol: water).
  • aqueous/organic typically 100 ⁇ L of 50:50 methanol: water.
  • Colo205 cells were seeded in 96 well plates and serially diluted compound was added to the wells in duplicate. Control groups included untreated cells, the compound diluent (0.1% DMSO alone) and culture medium without cells. The cells were then incubated for 72 or 96 hrs at 37C in an atmosphere of 5% CO2/95% humidity.
  • Reactions were carried out at 30 0 C and 21 nM AbI kinase. Final concentrations of the components of the coupled enzyme system were 2.5 mM phosphoenolpyruvate, 200 ⁇ M NADH, 60 ⁇ g/ml pyruvate kinase and 20 ⁇ g/ml lactate dehydrogenase.
  • An assay stock buffer solution was prepared containing all of the reagents listed above with the exception of ATP and the test compound of interest. The assay stock buffer solution (60 ⁇ l) was incubated in a 96 well plate with 2 ⁇ l of the test compound of interest at final concentrations typically spanning 0.002 ⁇ M to 30 ⁇ M at 30 0 C for 10 min.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des composés utiles en tant qu'inhibiteurs de la protéine kinases d'Aurora. L'invention propose également des compositions pharmaceutiquement acceptables comprenant ces composés et des procédés d'utilisation des composés et compositions dans le traitement de diverses maladies, affections et troubles. L'invention propose également des procédés de préparation des composés de l'invention.
PCT/US2008/057465 2007-03-20 2008-03-19 Aminopyrimidines utiles en tant qu'inhibiteurs de kinase WO2008115973A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CN200880014717A CN101675041A (zh) 2007-03-20 2008-03-19 用作激酶抑制剂的氨基嘧啶类化合物
CA002682195A CA2682195A1 (fr) 2007-03-20 2008-03-19 Aminopyrimidines utiles en tant qu'inhibiteurs de kinase
JP2009554707A JP2010522194A (ja) 2007-03-20 2008-03-19 キナーゼ阻害薬として有用なアミノピリミジン
MX2009010037A MX2009010037A (es) 2007-03-20 2008-03-19 Aminopirimidinas utiles como inhibidores de cinasas.
EP08732458A EP2142537A2 (fr) 2007-03-20 2008-03-19 Aminopyrimidines utiles en tant qu'inhibiteurs de kinase
AU2008228963A AU2008228963A1 (en) 2007-03-20 2008-03-19 Aminopyrimidines useful as kinase inhibitors
US12/562,181 US20100137305A1 (en) 2007-03-20 2009-09-18 Aminopyrimidines useful as kinase inhibitors

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US91901407P 2007-03-20 2007-03-20
US60/919,014 2007-03-20
US94677807P 2007-06-28 2007-06-28
US60/946,778 2007-06-28

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/562,181 Continuation US20100137305A1 (en) 2007-03-20 2009-09-18 Aminopyrimidines useful as kinase inhibitors

Publications (2)

Publication Number Publication Date
WO2008115973A2 true WO2008115973A2 (fr) 2008-09-25
WO2008115973A3 WO2008115973A3 (fr) 2008-12-04

Family

ID=39743123

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/057465 WO2008115973A2 (fr) 2007-03-20 2008-03-19 Aminopyrimidines utiles en tant qu'inhibiteurs de kinase

Country Status (8)

Country Link
US (1) US20100137305A1 (fr)
EP (1) EP2142537A2 (fr)
JP (2) JP2010522194A (fr)
CN (1) CN101675041A (fr)
AU (1) AU2008228963A1 (fr)
CA (1) CA2682195A1 (fr)
MX (1) MX2009010037A (fr)
WO (1) WO2008115973A2 (fr)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012521425A (ja) * 2009-03-23 2012-09-13 Ｍｓｄ株式会社 オーロラａ選択的阻害作用を有する新規アミノピリジン誘導体
JP2012521426A (ja) * 2009-03-24 2012-09-13 Ｍｓｄ株式会社 オーロラａ選択的阻害作用を有する新規アミノピリジン誘導体
WO2013143466A1 (fr) * 2012-03-27 2013-10-03 广东东阳光药业有限公司 Dérivé de pyrimidine substitué en tant qu'inhibiteur des kinases aurora
WO2014081689A1 (fr) * 2012-11-20 2014-05-30 Vertex Pharmaceuticals Incorporated Composés utiles comme inhibiteurs de l'indoléamine 2,3-dioxygénase
US20140187540A1 (en) * 2011-02-15 2014-07-03 The Johns Hopkins University Compounds and methods of use thereof for treating neurodegenerative disorders
US9296701B2 (en) 2012-04-24 2016-03-29 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors
US9340557B2 (en) 2013-03-12 2016-05-17 Vertex Pharmaceuticals Incorporated Substituted quinoxaline DNA-PK inhibitors
WO2016166604A1 (fr) * 2015-04-17 2016-10-20 Ludwig Institute For Cancer Research Ltd Inhibiteurs de plk4
US10039761B2 (en) 2013-10-17 2018-08-07 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
US10683293B2 (en) 2014-08-04 2020-06-16 Nuevolution A/S Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
US11110108B2 (en) 2016-09-27 2021-09-07 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors
US11447479B2 (en) 2019-12-20 2022-09-20 Nuevolution A/S Compounds active towards nuclear receptors
US11613532B2 (en) 2020-03-31 2023-03-28 Nuevolution A/S Compounds active towards nuclear receptors
US11780843B2 (en) 2020-03-31 2023-10-10 Nuevolution A/S Compounds active towards nuclear receptors

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100355750C (zh) 2000-09-15 2007-12-19 沃泰克斯药物股份有限公司 可用作蛋白激酶抑制剂的吡唑化合物
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
WO2004072029A2 (fr) 2003-02-06 2004-08-26 Vertex Pharmaceuticals Incorporated Compositions utiles en tant qu'inhibiteurs de proteine kinases
AR045047A1 (es) * 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
SG166827A1 (en) 2005-11-03 2010-12-29 Vertex Pharma Aminopyrimidines useful as kinase inhibitors
JP2010509231A (ja) 2006-11-02 2010-03-25 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼの阻害剤として有用なアミノピリジンおよびアミノピリミジン
WO2008077086A1 (fr) 2006-12-19 2008-06-26 Vertex Pharmaceuticals Incorporated Aminopyridines utiles comme inhibiteurs de protéine kinases
JP5520057B2 (ja) 2007-03-09 2014-06-11 バーテックス ファーマシューティカルズ インコーポレイテッド 蛋白キナーゼの阻害剤として有用なアミノピリミジン
CA2679701A1 (fr) 2007-03-09 2008-09-18 Vertex Pharmaceuticals Incorporated Utilisation des aminopyridines comme inhibiteurs de proteines kinases
JP5393489B2 (ja) * 2007-03-09 2014-01-22 バーテックス ファーマシューティカルズ インコーポレイテッド 蛋白キナーゼの阻害剤として有用なアミノピリミジン
CN101675041A (zh) * 2007-03-20 2010-03-17 沃泰克斯药物股份有限公司 用作激酶抑制剂的氨基嘧啶类化合物
WO2008128009A2 (fr) 2007-04-13 2008-10-23 Vertex Pharmaceuticals Incorporated Aminopyrimidines utilisees en tant qu'inhibiteurs de kinases
WO2008137621A1 (fr) 2007-05-02 2008-11-13 Vertex Pharmaceuticals Incorporated Aminopyrimidines servant d'inhibiteurs de kinases
JP5389785B2 (ja) 2007-05-02 2014-01-15 バーテックス ファーマシューティカルズ インコーポレイテッド キナーゼ阻害剤として有用なチアゾールおよびピラゾール
MX2010001137A (es) 2007-07-31 2010-03-31 Vertex Pharma Procesopara preparar 5-fluoro-1h-pirazol[3,4-b]piridin-3-amina y derivados del mismo.
US9023856B2 (en) 2011-11-04 2015-05-05 Cymabay Therapeutics, Inc. Methods for treating hyperuricemia in patients with gout using halofenate or halogenic acid and a second urate-lowering agent
US9187453B2 (en) 2012-03-28 2015-11-17 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2018026798A1 (fr) 2016-08-01 2018-02-08 Aptinyx Inc. Modulateurs de nmda spiro-lactame et leurs procédés d'utilisation
BR112019001921A2 (pt) 2016-08-01 2019-05-14 Aptinyx Inc. moduladores do receptor nmda de espiro-lactama e seus usos
CA3031537A1 (fr) 2016-08-01 2018-02-08 Aptinyx Inc. Modulateurs spiro-lactames des recepteurs nmda et leurs utilisations
AU2019215058A1 (en) * 2018-01-31 2020-09-17 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
GB201815018D0 (en) * 2018-09-14 2018-10-31 Univ Oxford Innovation Ltd Enantiomeric compounds

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003078423A1 (fr) * 2002-03-15 2003-09-25 Vertex Pharmaceuticals, Inc. Compositions s'utilisant comme inhibiteurs de proteine kinases
WO2004000833A1 (fr) * 2002-06-20 2003-12-31 Vertex Pharmaceuticals Incorporated Procedes pour la preparation de pyrimidines substituees et derives de pyrimidines utilises comme inhibiteurs des proteine-kinases
US20050038023A1 (en) * 2000-12-21 2005-02-17 David Bebbington Pyrazole compounds useful as protein kinase inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101675041A (zh) * 2007-03-20 2010-03-17 沃泰克斯药物股份有限公司 用作激酶抑制剂的氨基嘧啶类化合物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050038023A1 (en) * 2000-12-21 2005-02-17 David Bebbington Pyrazole compounds useful as protein kinase inhibitors
WO2003078423A1 (fr) * 2002-03-15 2003-09-25 Vertex Pharmaceuticals, Inc. Compositions s'utilisant comme inhibiteurs de proteine kinases
WO2004000833A1 (fr) * 2002-06-20 2003-12-31 Vertex Pharmaceuticals Incorporated Procedes pour la preparation de pyrimidines substituees et derives de pyrimidines utilises comme inhibiteurs des proteine-kinases

Cited By (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012521425A (ja) * 2009-03-23 2012-09-13 Ｍｓｄ株式会社 オーロラａ選択的阻害作用を有する新規アミノピリジン誘導体
JP2012521426A (ja) * 2009-03-24 2012-09-13 Ｍｓｄ株式会社 オーロラａ選択的阻害作用を有する新規アミノピリジン誘導体
US9382229B2 (en) * 2011-02-15 2016-07-05 The Johns Hopkins University Compounds and methods of use thereof for treating neurodegenerative disorders
US20140187540A1 (en) * 2011-02-15 2014-07-03 The Johns Hopkins University Compounds and methods of use thereof for treating neurodegenerative disorders
WO2013143466A1 (fr) * 2012-03-27 2013-10-03 广东东阳光药业有限公司 Dérivé de pyrimidine substitué en tant qu'inhibiteur des kinases aurora
US9376448B2 (en) 2012-04-24 2016-06-28 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors
US11021465B2 (en) 2012-04-24 2021-06-01 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors
US11008305B2 (en) 2012-04-24 2021-05-18 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors
US9296701B2 (en) 2012-04-24 2016-03-29 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors
US10501439B2 (en) 2012-04-24 2019-12-10 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors
US9592232B2 (en) 2012-04-24 2017-03-14 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors
US9878993B2 (en) 2012-04-24 2018-01-30 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors for treatment of cancer
US9925188B2 (en) 2012-04-24 2018-03-27 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors and uses thereof
US10442791B2 (en) 2012-04-24 2019-10-15 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors
US10391095B2 (en) 2012-04-24 2019-08-27 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors
US10076521B2 (en) 2012-04-24 2018-09-18 Vertex Pharamceuticals Incorporated DNA-PK inhibitors
WO2014081689A1 (fr) * 2012-11-20 2014-05-30 Vertex Pharmaceuticals Incorporated Composés utiles comme inhibiteurs de l'indoléamine 2,3-dioxygénase
US9499497B2 (en) 2012-11-20 2016-11-22 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of indoleamine 2,3-dioxygenase
US10258627B2 (en) 2013-03-12 2019-04-16 Vertex Pharmaceutical Incorporated DNA-PK inhibitors
US9340557B2 (en) 2013-03-12 2016-05-17 Vertex Pharmaceuticals Incorporated Substituted quinoxaline DNA-PK inhibitors
US9987284B2 (en) 2013-03-12 2018-06-05 Vertex Pharmaceuticals Incorporated Substituted benzooxadiazole DNA-PK inhibitors
US11813267B2 (en) 2013-03-12 2023-11-14 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors
US10786512B2 (en) 2013-03-12 2020-09-29 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors
US10973830B2 (en) 2013-03-12 2021-04-13 Vertex Pharmaceuticals Incorporated Substituted quinoxaline DNA-PK inhibitors
US9359380B2 (en) 2013-03-12 2016-06-07 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors
US10716789B2 (en) 2013-10-17 2020-07-21 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
US10039761B2 (en) 2013-10-17 2018-08-07 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
US10683293B2 (en) 2014-08-04 2020-06-16 Nuevolution A/S Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
US10689383B2 (en) 2014-08-04 2020-06-23 Nuevolution A/S Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
US11254681B2 (en) 2014-08-04 2022-02-22 Nuevolution A/S Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
AU2016247858B2 (en) * 2015-04-17 2020-10-15 Ludwig Institute For Cancer Research Ltd. PLK4 inhibitors
US10752612B2 (en) 2015-04-17 2020-08-25 Ludwig Institute For Cancer Research Ltd PLK4 inhibitors
WO2016166604A1 (fr) * 2015-04-17 2016-10-20 Ludwig Institute For Cancer Research Ltd Inhibiteurs de plk4
US11110108B2 (en) 2016-09-27 2021-09-07 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors
US11980633B2 (en) 2016-09-27 2024-05-14 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors
US11447479B2 (en) 2019-12-20 2022-09-20 Nuevolution A/S Compounds active towards nuclear receptors
US11613532B2 (en) 2020-03-31 2023-03-28 Nuevolution A/S Compounds active towards nuclear receptors
US11780843B2 (en) 2020-03-31 2023-10-10 Nuevolution A/S Compounds active towards nuclear receptors

Also Published As

Publication number Publication date
US20100137305A1 (en) 2010-06-03
AU2008228963A1 (en) 2008-09-25
CN101675041A (zh) 2010-03-17
MX2009010037A (es) 2009-11-05
CA2682195A1 (fr) 2008-09-25
JP2013237703A (ja) 2013-11-28
JP2010522194A (ja) 2010-07-01
WO2008115973A3 (fr) 2008-12-04
EP2142537A2 (fr) 2010-01-13

Similar Documents

Publication Publication Date Title
EP2142537A2 (fr) Aminopyrimidines utiles en tant qu'inhibiteurs de kinase
EP1951716B1 (fr) Aminopyrimidines utiles en tant qu inhibiteurs de la kinase
US8268811B2 (en) Thiazoles and pyrazoles useful as kinase inhibitors
EP2152696B1 (fr) Aminopyrimidines servant d'inhibiteurs de kinases
US20110060013A1 (en) Thiazoles and pyrazoles useful as kinase inhibitors
US20110046104A1 (en) Aminopyrimidines useful as kinase inhibitors
US8455507B2 (en) Aminopyrimidines useful as kinase inhibitors
EP2148931A2 (fr) Méthodes pour la découverte d'inhibiteurs des kinases aurora en tant que médicaments
US20140037754A1 (en) Aminopyrimidines useful as kinase inhibitors
US20140303137A1 (en) Aminopyrimidines useful as kinase inhibitors

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880014717.4

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2682195

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2009554707

Country of ref document: JP

Ref document number: MX/A/2009/010037

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008228963

Country of ref document: AU

Ref document number: 579995

Country of ref document: NZ

Ref document number: 3403/KOLNP/2009

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2008732458

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2008228963

Country of ref document: AU

Date of ref document: 20080319

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08732458

Country of ref document: EP

Kind code of ref document: A2